{
    "clinical_study": {
        "@rank": "57160", 
        "arm_group": {
            "arm_group_label": "ritmonutra and placebo", 
            "arm_group_type": "Placebo Comparator", 
            "description": "ritmonutra 2 tablets/day by mouth for 4 weeks sugar pill manufatured to simulate ritmonutra: 2 tablets/day by mouth for 4 weeks"
        }, 
        "brief_summary": {
            "textblock": "it is a prospective, randomized, double-blinded, crossover study on the use of an\n      association of omega 3 fatty acids, astaxanthin, vitamin E and hawthorn (ritmonutra) in\n      subject affected by symptomatic supraventricular ectopic beats without structural heart\n      disease.\n\n      The study will evaluate the reduction of the number of supraventricular ectopic beats and\n      symptoms related."
        }, 
        "brief_title": "Use of Ritmonutra in Subjects Affected by Supraventricular Ectopic Beats Without Structural Heart Disease", 
        "condition": "Arrhythmia", 
        "condition_browse": {
            "mesh_term": [
                "Arrhythmias, Cardiac", 
                "Heart Diseases", 
                "Atrial Premature Complexes", 
                "Cardiac Complexes, Premature"
            ]
        }, 
        "detailed_description": {
            "textblock": "24 subjects without structural heart disease with a minimum of 300 supraventricular ectopic\n      beats in 24 hours will be enrolled in the two participating centers and randomized to the\n      treatment or to the placebo for 4 weeks. At the end of the first treatment period, a 24\n      hours Holter ECG will be performed. After 1 week of wash-out therapy, subjects will be\n      crossed over to the other treatment for 4 weeks. Another 24 hours Holter ECG will be\n      performed at the end of the study. During the baseline visit and during each follow up\n      visit, symptom score and quality of life questionnaires will be completed by the subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age: 18 to 80 years\n\n          -  symptomatic supraventricular ectopic beats (at least 300 in 24 hours recording)\n\n          -  no structural heart disease evaluated with ecg, echocardiography, stress test and\n             chest x-ray.\n\n          -  no antiarrhythmic drug in use.\n\n        Exclusion Criteria:\n\n          -  acute systemic illness\n\n          -  preexcitation\n\n          -  3 or more consecutive ectopic beats\n\n          -  vascular disease\n\n          -  diabetes\n\n          -  asthma\n\n          -  soy allergy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02087033", 
            "org_study_id": "RN-tvg-00313b"
        }, 
        "intervention": [
            {
                "arm_group_label": "ritmonutra and placebo", 
                "description": "2 tablets a day by mouth for 4 weeks", 
                "intervention_name": "ritmonutra", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "ritmonutra rottapharm"
            }, 
            {
                "arm_group_label": "ritmonutra and placebo", 
                "description": "sugar pill manufactured to simulated ritmonutra: 2 tablets a day for 4 weeks", 
                "intervention_name": "placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "supraventricular ectopic beats", 
        "lastchanged_date": "March 7, 2014", 
        "location": [
            {
                "contact": {
                    "email": "flavio.doni@fastwebnet.it", 
                    "last_name": "flavio doni, MD", 
                    "phone": "0039035604416"
                }, 
                "facility": {
                    "address": {
                        "city": "Ponte San Pietro", 
                        "country": "Italy", 
                        "state": "Bergamo", 
                        "zip": "24100"
                    }, 
                    "name": "Policlinico San Pietro"
                }, 
                "investigator": {
                    "last_name": "flavio doni, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "riccardo.cappato@grupposandonato.it", 
                    "last_name": "riccardo cappato, MD", 
                    "phone": "0252774337"
                }, 
                "facility": {
                    "address": {
                        "city": "San Donato Milanese", 
                        "country": "Italy", 
                        "state": "Milan", 
                        "zip": "20097"
                    }, 
                    "name": "Policlinico San Donato"
                }, 
                "investigator": {
                    "last_name": "Cristina Balla, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Randomized, Double-blinded, Cross-over Study on the Use of Ritmonutra, a Nutraceutical Product Composed of Omega 3 Fatty Acids, Astaxanthin, Vitamin E and Hawthorn in Subjects Affected by Supraventricular Ectopic Beats Without Structural Heart Disease", 
        "overall_contact": {
            "email": "riccardo.cappato@grupposandonato.it", 
            "last_name": "riccardo cappato, MD", 
            "phone": "00390252774337"
        }, 
        "overall_official": {
            "affiliation": "Policlinico San Donato", 
            "last_name": "riccardo cappato, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "the primary outcome will evaluate the reduction of the number of supraventricular ectopic beats after 4 weeks of treatment using a 24 h holter recording.", 
            "measure": "Efficacy in reduction of supraventricular ectopic beats", 
            "safety_issue": "No", 
            "time_frame": "4 weeks of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02087033"
        }, 
        "responsible_party": {
            "investigator_affiliation": "IRCCS Policlinico S. Donato", 
            "investigator_full_name": "Riccardo Cappato", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "the secodary outcome will evaluate the reduction of symptoms related to supraventricular ectopic beats using a symptom score and a quality of life questionnaire.", 
            "measure": "Efficacy in reduction of symptoms related to supraventricular ectopic beats", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "source": "IRCCS Policlinico S. Donato", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "IRCCS Policlinico S. Donato", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}